Hormonal
Central nervous system (CNS) inflammation, specifically via IL-1β signaling, induces skeletal muscle atrophy through the activation of the hypothalamic-pituitary-adrenal (HPA) axis and subsequent glucocorticoid release, independent of direct peripheral cytokine action on muscle.
In chronic inflammatory conditions, muscle loss is driven significantly by the brain's response to inflammation (via the HPA axis and stress hormones), not just by the inflammation hitting the muscle directly. This suggests that interventions targeting the central inflammatory response or stress hormone pathways may be necessary to prevent muscle wasting, rather than just focusing on local muscle nutrition or exercise.
We demonstrate that central nervous system (CNS)–delimited interleukin 1β (IL-1β) signaling alone can evoke a catabolic program in muscle, rapidly inducing atrophy. This effect is dependent on hypothalamic–pituitary–adrenal (HPA) axis activation, as CNS IL-1β–induced atrophy is abrogated by adrenalectomy.
Why this rating
High-quality mechanistic evidence using multiple animal models (mice and rats), genetic knockouts (MC4RKO), surgical interventions (adrenalectomy), and pharmacological blockade, though results are not directly translatable to humans without further study.
Source
Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic–pituitary–adrenal axis
Theodore P. Braun et al. · The Journal of Experimental Medicine · 2011
DOI 10.1084/jem.20111020
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →